Corcept Therapeutics Incorporated cash flow to debt ratio of 2.33K% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.

Corcept Therapeutics Incorporated's free cash flow has decreased -27.62% from $195.90M last year to $141.78M, signaling decreasing performance

Corcept Therapeutics Incorporated's debt to equity ratio is 0.02, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Corcept Therapeutics Incorporated's debt has increased relative to shareholder equity from 0.01 last year to 0.02 today, signaling weakened financials

Corcept Therapeutics Incorporated has a net debt to EBITDA ratio of 0.00x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

Corcept Therapeutics Incorporated earns at least as much interest as it pays. Interest obligations are fully covered.

Corcept Therapeutics Incorporated's profit margin has decreased (-69.91%) in the last year from 20.70% to 6.23%, signaling decreasing performance

Corcept Therapeutics Incorporated's short-term assets of $485.46M exceed its short-term liabilities of $166.09M

Corcept Therapeutics Incorporated's return on assets of 5.88% is higher than the 5.00% threshold, indicating efficient asset utilization

Corcept Therapeutics Incorporated's return on equity of 7.50%, is lower than 15.00%, indicating bad performance

Corcept Therapeutics Incorporated's operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

Corcept Therapeutics Incorporated had positive net income in 5.00 out of 5 years, indicating stable and consistent earnings

Corcept Therapeutics Incorporated has positive free cash flow, indicating the company generates cash after capital expenditures

Corcept Therapeutics Incorporated has a free cash flow yield of 1.46%, which is below the 2.00% threshold, indicating limited cash return relative to market value

Corcept Therapeutics Incorporated's yearly earnings has decreased -28.68% since last year from $139.73M to $99.65M, signaling decreasing performance

Corcept Therapeutics Incorporated's yearly revenue has increased 12.79% since last year from $675.04M to $761.41M, signaling increasing performance

ROIC -1.23% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Corcept Therapeutics Incorporated's 3-year revenue CAGR of 23.74% is positive, indicating growing revenue over the past 3 years

Corcept Therapeutics Incorporated had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance

Corcept Therapeutics Incorporated had positive ROE in 5.00 out of 5 years, indicating consistent and reliable returns on equity

Corcept Therapeutics Incorporated is overvalued relative to its fair value price of 15.89 based on Discounted Cash Flow model

Corcept Therapeutics Incorporated has an earnings yield of 0.51%, which is below the 4.00% threshold, indicating the stock may be expensive relative to its earnings

Corcept Therapeutics Incorporated is overvalued relative to its fair value price of 5.58 based on EBITDA multiple model

Corcept Therapeutics Incorporated has an EV/EBITDA ratio of 140.41x, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings

Corcept Therapeutics Incorporated is overvalued relative to its fair value price of 30.04 based on Earnings Fair Value model

Corcept Therapeutics Incorporated has no meaningful EPS growth rate; PEG ratio cannot be computed.

Corcept Therapeutics Incorporated has a price-to-book ratio of 14.81x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Corcept Therapeutics Incorporated has a price-to-sales ratio of 12.28x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue